Cell and gene therapy market seen topping $44B by 2030

The Business Research Company projects the global cell and gene therapy market will surpass $44 billion by 2030, driven by oncology demand, rare disease treatments and faster commercialization of allogeneic therapies. North America and the U.S. are expected to lead the market as manufacturing, clinical trials and supply chain capacity expand.

Why it matters: - Cell and gene therapy is moving from a niche segment to a major pharmaceutical category, with the market projected to exceed $44 billion by 2030. - The growth reflects demand for therapies that can treat cancers, rare genetic disorders and chronic diseases where conventional drugs often fall short. - The market’s expansion is also reshaping manufacturing, logistics and clinical development across biotech and pharma.

What happened: - The Business Research Company released an analysis of the global cell and gene therapy market covering forecasts through 2035. - The report projects the market will surpass $44 billion by 2030. - North America is forecast to be the largest regional market in 2030 at $20 billion, up from $8 billion in 2025. - The U.S. is expected to be the largest national market at $19 billion in 2030, up from $7 billion in 2025. - Cell therapy is projected to be the largest product segment, reaching $28 billion and representing 64% of the total market by 2030. - The market is expected to grow at a 23% compound annual growth rate through 2030.

The details: - The Personalized Cell Therapy market is forecast to reach about $56 billion by 2030, with cell and gene therapies making up about 79% of that total. - Within the broader pharmaceuticals market, cell and gene therapies are projected to account for nearly 2% of the $2,496 billion market expected in 2030. - North America’s growth is linked to rising therapy approvals and commercialization, higher investment in regenerative medicine and genomic innovation, broader use of personalized treatment strategies and more specialized manufacturing infrastructure. - U.S. growth is tied to CAR-T adoption, next-generation gene editing, demand for rare disease treatments, expanded viral vector production and more cell processing capacity. - The cell therapy segment is being supported by CAR-T and stem cell treatments, regenerative medicine demand, better cell engineering and more clinical trials in cancer and autoimmune diseases. - The market is segmented across applications including oncology and neurological disorders, with hospitals, ambulatory surgical centers, cancer care facilities and wound care centers among the key end users. - Rising cancer prevalence is a major growth driver, adding about 1.3% annually to market growth. - Chronic and genetic disease burden is expected to contribute about 0.8% annually. - Aging populations are expected to add about 0.5% annually. - The most promising growth area is the combined cell therapy and gene therapy opportunity, which is expected to exceed $28 billion by 2030. - The cell therapy market is expected to increase by $17 billion from 2025 to 2030, while gene therapy is expected to add about $11 billion. - Cryoport Inc. led the market in 2025 with a 4% global sales share. - Cryoport’s supply chain business focuses on cold chain logistics, temperature-controlled storage and transportation for cell and gene therapy products. - Major companies in the market include Thermo Fisher Scientific, UPS, Lonza, BioLife Solutions, Cytiva, Avantor, PCI Pharma Services, Almac Group and Catalent. - The top 10 players held a combined 24% of revenue in 2025, indicating a moderately fragmented market. - Entry barriers include complex regulation, manufacturing difficulty, technical requirements and the need to prove safety, efficacy and scalability. - Key raw material suppliers include Thermo Fisher Scientific, Merck KGaA, Lonza, Sartorius, Charles River Laboratories, Danaher, Repligen, Bio-Techne, Agilent and PerkinElmer. - Major distributors include McKesson, Cardinal Health, Cencora, Owens & Minor, Phoenix Pharmahandel, Zuellig Pharma, Sinopharm, DHL Supply Chain Healthcare Division and others. - Leading end users include Novartis Gene Therapies, Bluebird Bio, Spark Therapeutics, Sarepta Therapeutics, BioMarin, Orchard Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Moderna, BioNTech, Kite Pharma, Genentech, Regeneron, AstraZeneca, Johnson and Johnson Innovative Medicine and Takeda Rare Disease Therapeutics.

Between the lines: - The report points to a market shifting toward off-the-shelf and allogeneic therapies, which could make advanced treatments more scalable and accessible. - Strong demand in oncology is still the clearest near-term revenue engine because these therapies can command high prices and address late-stage disease. - The concentration of logistics and manufacturing capability suggests that supply chain execution remains a competitive advantage, not just a back-office function. - The report also highlights a broader move toward curative and personalized medicine, which could favor companies with gene editing, cell modification and biomanufacturing expertise.

What’s next: - Companies are expected to keep expanding manufacturing infrastructure, bioprocessing tools and gene editing platforms to meet demand. - Partnerships between biotech firms, research organizations and healthcare providers are likely to remain central to commercialization. - Regulatory approvals, clinical trial results and manufacturing scale-up will continue to determine which therapies gain market share. - The report flags allogeneic cell therapies as an important commercialization trend, including recent launches such as Cipla and Stempeutics Research’s Ciplostem in India.

The bottom line: - Cell and gene therapy is poised for sustained double-digit growth through 2030, with cancer care, rare diseases and scalable manufacturing driving the next phase of market expansion.